Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDX 
Becton Dickinson and Company (BDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: BDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $217.82
1 Year Target Price $217.82
| 4 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.76% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 50.87B USD | Price to earnings Ratio 34.37 | 1Y Target Price 217.82 |
Price to earnings Ratio 34.37 | 1Y Target Price 217.82 | ||
Volume (30-day avg) 17 | Beta 0.28 | 52 Weeks Range 162.35 - 249.34 | Updated Date 07/11/2025 |
52 Weeks Range 162.35 - 249.34 | Updated Date 07/11/2025 | ||
Dividends yield (FY) 2.42% | Basic EPS (TTM) 5.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.18% | Operating Margin (TTM) 16.01% |
Management Effectiveness
Return on Assets (TTM) 3.69% | Return on Equity (TTM) 5.89% |
Valuation
Trailing PE 34.37 | Forward PE 11.55 | Enterprise Value 69459815985 | Price to Sales(TTM) 2.44 |
Enterprise Value 69459815985 | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 3.33 | Enterprise Value to EBITDA 14.94 | Shares Outstanding 286607008 | Shares Floating 285928154 |
Shares Outstanding 286607008 | Shares Floating 285928154 | ||
Percent Insiders 0.56 | Percent Institutions 92.62 |
Upturn AI SWOT
Becton Dickinson and Company
Company Overview
History and Background
Becton Dickinson and Company (BD) was founded in 1897. Initially a medical supply company, BD evolved into a global medical technology company, playing a key role in advancing healthcare.
Core Business Areas
- BD Medical: Produces medical devices such as syringes, needles, and infusion sets for medication delivery.
- BD Life Sciences: Offers diagnostic systems and reagents for a range of applications, including infectious disease testing, cancer diagnostics, and flow cytometry.
- BD Interventional: Focuses on products for peripheral intervention, surgery, and urology, including catheters, balloons, and stents.
Leadership and Structure
Tom Polen serves as Chairman, CEO, and President. BD operates with a matrix organizational structure, encompassing global business units and regional operations.
Top Products and Market Share
Key Offerings
- BD Vacutainer Tubes: Used for blood collection. Globally used. Competitors: Greiner Bio-One, Sekisui Diagnostics.
- BD Alaris Infusion System: Infusion system used in hospitals. Competitors: Baxter International, ICU Medical.
- BD FACS Flow Cytometers: Flow cytometer used for cellular analysis. Competitors: Thermo Fisher Scientific, Bio-Rad Laboratories.
Market Dynamics
Industry Overview
The medical technology industry is driven by innovation, regulatory approvals, and healthcare spending. Trends include personalized medicine, digital health, and point-of-care diagnostics.
Positioning
BD is a leading global medical technology company with a strong reputation for innovation, quality, and customer service. Its broad product portfolio and global presence provide a competitive advantage.
Total Addressable Market (TAM)
The global medical technology market is valued at approximately $500 billion. BD is well-positioned to capture a significant portion of this TAM through its diverse portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Global brand recognition
- Extensive product portfolio
- Strong distribution network
- Commitment to innovation
- Experienced management team
Weaknesses
- Exposure to regulatory risks
- Dependence on hospital spending
- Integration challenges from acquisitions
- Competition from low-cost providers
Opportunities
- Expanding into emerging markets
- Developing new diagnostic technologies
- Acquiring complementary businesses
- Leveraging digital health solutions
- Personalized Medicine
Threats
- Increased competition
- Pricing pressures
- Economic downturns
- Product recalls
- Changing healthcare regulations
Competitors and Market Share
Key Competitors
- BSX
- TMO
- DHR
- SYK
Competitive Landscape
BD competes on the basis of product quality, innovation, customer service, and price. It holds competitive advantages in specific market segments.
Major Acquisitions
Bard
- Year: 2017
- Acquisition Price (USD millions): 24000
- Strategic Rationale: Expanded BD's portfolio in the faster-growing vascular and urology categories.
Growth Trajectory and Initiatives
Historical Growth: BD has grown both organically and through acquisitions, expanding its product portfolio and geographic reach.
Future Projections: Analyst estimates vary, but generally project continued growth driven by innovation, market expansion, and strategic acquisitions.
Recent Initiatives: Recent initiatives include investments in R&D, expansion into emerging markets, and strategic acquisitions of medical device companies.
Summary
Becton Dickinson is a strong player in the medical technology space due to its long history, global brand, and expansive product portfolio. Growth is dependent on the rate of continued innovation, strategic acquisitions and the healthcare spend. BD needs to maintain a high level of service in the face of continued cost pressure and competition. Overall they are fairly stable and considered a sound investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Becton Dickinson and Company
Exchange NYSE | Headquaters Franklin Lakes, NJ, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Chairman Mr. Thomas E. Polen Jr. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 70000 | Website https://www.bd.com |
Full time employees 70000 | Website https://www.bd.com | ||
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.